664
Views & Citations10
Likes & Shares
A lymph node based T cell lymphoma which originates from a T follicular
helper cell phenotype may cogitate the angio-immunoblastic T cell lymphoma
(AITL) or an angio-immunoblastic lymphadenopathy with dysproteinaemia (AILD).
At an estimated 1%-2% of Non-Hodgkin’s lymphoma, it may emerge at a median age
of 59-65 years with a slight male predominance. Approximately 70% individuals
exemplify B symptoms such as fever, weight loss greater than 10% of the body
weight, drenching night sweats, lymph node enlargement, hepato-splenomegaly
(74%) and skin involvement (50%). The immune hyper-active lymphoma may
enunciate an elevation of the erythrocyte sedimentation rate (ESR), reactive
autoimmune rheumatoid factor (RF), anti-smooth muscle antibody and coexistent
circulating immune complexes or a cold agglutinin reaction. An all prevailing
dysregulation of the follicular T helper (TFH) lymphocytes ensues within the
disorganized germinal centres with an emerging angio-immunoblastic T cell
lymphoma. Immunoblasts, B lymphocytes, plasma cells, eosinophils, histiocytes
and epitheloid cells may predominate with diverse immune reactive T cell
antigens such as CD3+, CD4+, CD8-, CXCL13+, CD10+, BCL6-, CD19+, C20+, CD1a+,
CD21+, CD23+ and TdT. Multiple genetic aberrations such as TET2 (47%-73%), DN
MT 3A (33%) and IDH2-R172 (20-40%) may be exemplified. The classic combination
of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) is a gold
standard of therapy with AITL. Solitary agents employed in combination with
CHOP regimen are romidepsin, belinostat or pralatrexate. Median 5 year survival
of the lymphoma (AITL) appears at an estimated (32%).
Keywords: Angio-immunoblastic
T cell lymphoma, Immune hyper-activity, Follicular T helper (TFH) lymphocyte
malignancy
PREFACE
Angio-immunoblastic T cell lymphoma (AITL) may be designated as a lymph
node based T cell lymphoma which originates from a T follicular helper cell
phenotype by the world health organization [1]. Angio-immunoblastic T cell
lymphoma (AITL) may constitute as a distinct, infrequent subcategory of matures
peripheral T cell lymphoma (PTCL). The lymphoma (AITL) presents as an advanced
stage disease and demonstrates an anomalous and oligoclonal T cell
proliferation. Atypical laboratory findings and co-existent autoimmune disease
may obscure initial diagnosis [2]. Angio-immunoblastic T cell lymphoma (AITL)
may simultaneously be cogitated as angio-immunoblastic lymphadenopathy with
dysproteinaemia (AILD), immunoblastic lymphadenopathy or lymphogranulomatosis X
[2,3]. The disorder was labelled as a benign immune activation of B lymphocytes
despite the fatal course of disease. Evaluation of clone specific T and B
lymphocytes may confirm a malignant and T lymphocytic manifestation of the
neoplasm. Hence the current terminology of angio-immunoblastic T cell lymphoma
(AITL) may be preferred.
DISEASE CHARACTERISTICS
Angio-immunoblastic T
cell lymphoma (AITL) comprises of an estimated 1%-2% of Non-Hodgkin’s lymphoma
and roughly one fifth (20%) of the annual incidence of peripheral T cell
lymphoma (PTCL). Angio-immunoblastic T cell lymphoma (AITL) generally
implicates the elderly with a median age of disease emergence at 59-65 years
with a slight male predominance [2,3]. The lymphoma (AITL) may be frequent in
Europe (28.7%) in contrast to the Asian (17.9%) subcontinent.
Angio-immunoblastic T cell lymphoma (AITL) may concur with an Epstein Barr
viral (EBV) infection (70% to 100%). The B lymphocytes denominate a perpetual
viral infection whereas the malignant
CLINICAL ELUCIDATION
The subjects may enunciate non-specific constitutional symptoms,
transient physical signs and inconclusive serological or radiographic features,
thus detection of the disorder may be delayed by several weeks or months.
Individuals incriminated with the Non-Hodgkin’s lymphoma (AITL) may exemplify B
symptoms(70%) such as fever, weight loss greater than 10% of the body weight,
drenching night sweats, lymph node enlargement, hepato-splenomegaly (74%) and
skin involvement (50%) [2,3]. Angio-immunoblastic T cell lymphoma (AITL) or previous
angio-immunoblastic lymphadenopathy with dysproteinemia (AILD) with clinical
features characteristic of a lymphoma may display a maculo-papular rash
(simulating a viral rash), poly-arthritis (sero-positive), fever, pruritus,
lymph node enlargement, night sweats and weight loss. Additionally edema, acute
abdomen, disseminated bacterial infection and herpes virus type 6 or associated
viral infections may be demonstrated. Discordant clinical manifestations such
as a sick sinus syndrome and collagen vascular disease such as rheumatoid
arthritis and dermatomyositis may indicate the presence of an AITL. AITL may
simulate an infection by M. tuberculosis with the consequent initiation of
anti-tubercular therapy. Proliferative glomerular-nephritis concomitant to the
lymphoma (AITL) may be exceptional. Pulmonary involvement may be indicated by
hypoxemia, interstitial pneumonia or bronchopneumonia. Subjects with
bronchopneumonia may demonstrate co-existent opportunistic infections such as
pneumonia due to Pneumocystis jirovecii,
dyspnoea and peripheral edema. The lymphoma may be preceded by an allergic
reaction, infection, drug exposure or penicillin administration [2,3]. Minimal
lymph node enlargement of the magnitude of 1.5 to 3.0 cm on computerized
tomography (CT) and diverse standard uptake values (SUVs) on a positron
emission tomography (PET) may be elucidated. Majority (70%) of the individuals
demonstrate an implicated bone marrow. AITL exhibits an infrequent preliminary
stage disease at an estimated (10%). Hepatomegaly and splenomegaly may
initially be moderate. Antecedent skin rash may appear in approximately 20%-50%
instances. Dermal manifestations arise as urticarial rash or tumor like
nodules. Administration of antimicrobial agents or the exceptional overt, cutaneous
variant of AITL may delineate multitudinous skin rashes. Extra-nodal
incrimination may be infrequent with AITL. Immune hyper-activity may be
enunciated with an elevation of the erythrocyte sedimentation rate (ESR),
reactive autoimmune rheumatoid factor (RF), anti-smooth muscle antibody and
coexistent circulating immune complexes or a cold agglutinin reaction. Serum
protein electrophoresis may depict the polyclonal nature of dysproteinemia and
gammopathy [3,5]. A clone specific plasmacytosis may infrequently concur with a
monoclonal gammopathy in an estimated 10% instances. Autoimmune induced warm
antibody (direct anti-globulin test - DAT) hemolytic anemia may appear as the
presenting symptom. Eosinophilia may emerge with or without a concomitant infectious
etiology. The peripheral blood smear rarely depicts circulating malignant cells
which may be suitably enunciated on a flow cytometry of the peripheral blood
[2,3].
GENESIS OF THE LYMPHOMA
Angio-immunoblastic T cell lymphoma (AITL) as engendered from the
follicular helper T lymphocyte (TFH) subset may exemplify a genetic concurrence
by molecular mechanisms. The follicular helper T lymphocyte (TFH) functions as
a critical controlling mechanism of B cell differentiation and activation
within the germinal centre. Antigenic stimulation of the germinal centres may
incite a B cell hyperactivity [4,5]. The follicular helper T lymphocytes (TFH)
catalyses the evolution of peripherally dispersed secondary lymphoid tissue
containing centroblasts into centrocytes. The lymphocytic interrelation
consequently activates the differentiation of lymphoid cells into plasma cells
or memory B cells. Inception of immune tolerance within the follicular helper T
(TFH) lymphocyte compartment may be critical for restricting the genesis of
auto immune disorders. Nevertheless, a comprehensive dysregulation of the
follicular T helper (TFH) lymphocytes may ensue within the disorganized
germinal centres with a subsequent emergence of angio-immunoblastic T cell
lymphoma (AITL) [5,6].
MORPHOLOGICAL ELUCIDATION
A lymph node biopsy may discern AITL. The malignant follicular helper T
(TFH) lymphocytic component may constitute a miniscule fraction of the lymph
node neoplasm similar to the Reed Sternberg cells denominated in Hodgkin’s
disease. Lymph node architecture may be obliterated with an absence of
follicles. Immunological cells such as immunoblasts, B lymphocytes, plasma
cells, eosinophils, histiocytes and epitheloid cells may be abundant. The follicular
dendritic cells (FDCs) and vasculature with proliferative, plump endothelium
may propagate aberrantly and randomly [4,5]. The aggregates of malignant
follicular helper T (TFH) lymphocytes may about the high endothelial venules
(HEVs). The lymphoma may enunciate as a systemic disease with lesions confined
to the lymph node, bone marrow, spleen, liver and skin. Malignant conversion of
the lymph node with characteristic manifestations may delineate an effaced
nodal architecture, focally preserved lymphoid sinuses, a polymorphic
infiltration of lymphoid cells and a prominent proliferation of post capillary
venules. The cellular infiltrate may comprise of miniature lymphocytes, plasma
cells, immunoblasts, eosinophils and multinucleated giant cells. The lymph node
may be persistently devoid of normal, uninvolved germinal centres. The germinal
centres may be constituted of disordered aggregates of pale histiocytes,
immunoblasts and enlarged epitheloid cells, appropriately termed as the “burnt
out germinal centres”. The germinal centres may focally recapitulate the
appearance of granulomas. The conventional germinal centres may exceptionally
display hyperplasia of the surrounding lymphoid follicles [4]. Proliferation of
dendritic reticulum cell clusters, immune reactive for desmin, may be
elucidated. An amorphous, eosinophilic intercellular substance reactive for
periodic acid schiff’s (PAS) stain may be disseminated through the lymph node
architecture. Capsular and peri-capsular infiltration of tumour cells may be
frequent. A polyclonal immunoglobulin configuration may be elucidated by the
immunoperoxidase stain. B lymphocytes with immune reactivity to the Epstein
Barr virus (EBV+) may be detected in a majority (75%) of instances. The
lymphoid aggregates may vary from reversible and reactive to malignant and
aggressive in countenance [4,6]. Clone specific proportions of B and T
lymphocytes may be discerned. An
aberrant cellular composition may be discerned such as immunoblasts, miniature
lymphocytes with convoluted nuclei and thick membrane or clear cells. The
particular subtypes may denominate an aggravated clinical course.
IMMUNE PHENOTYPE AND IN SITU HYBRIDIZATION
Immune reactivity to diverse T cell antigens may be employed to
ascertain the presence of tumor cells such as CD3+, CD4+, CD8-, CXCL13+, CD10+,
BCL6-, CD19+, C20+, CD1a+, CD21+, CD23+ and TdT. A clone specific T lymphocyte
population may be elucidated in the majority (75%) instances [6,7]. The
malignant follicular helper T (TFH) lymphocytes may depict a phenotype of
immune reactive CD3+, CD4+, CD10+. An alpha /beta T cell receptor may be
elucidated with a frequent, anomalous negativity for CD5- and/or CD7-. An
estimated one fifth (20%) instances may display a CD30+ immune expression. An
immune reactive CXCL13+ may be particularly specific and consistently
elucidated in the cytoplasm, in contrast to CD10, for denominating the
lymphoma. The follicular helper T (TFH) lymphocytes may manifest the program
death receptor 1 (PD-1), ICOS, BCL6 and CD200 [3]. The aforementioned immune
molecular expression may demarcate the lymphoma (AITL) from diverse benign
lympho-proliferative disorders and subcategories of PTCL with an identical
genesis from a follicular helper T (TFH) cell. An immune reactive CD21+ may demarcate
the follicular dendritic cells (FDCs) from the intermingled follicular helper T
(TFH) cells and high endothelial venules (HEVs) [7,8]. Majority of the enlarged
B lymphocytes may depict a reactive Epstein Barr virus encoded small RNAs
(EBER) by in situ hybridization, indicating an ongoing viral infection (EBV),
whereas the malignant follicular helper T (TFH) lymphocytes may be non-reactive
to EBER.
MOLECULAR ASSAY
A majority (90%) of instances of angio-immunoblastic T cell lymphoma
(AITL) may depict an anomalous karyotype, which may or may not belong to the
particular clone of malignant T lymphocytes. Trisomy of chromosomes 3 and 5 may
be a frequent aberration. The TP53 oncogene may be infrequently decimated
[2,3]. However, occurrence of clone specific complications may indicate a poor
prognosis. As the lymphoma (AITL) may be devoid of characteristic anomalies,
the development of therapeutic possibilities may be lacking. Immune reactivity
to clone specific CD4+ T cells may be delineated in a majority (80%) of
instances of angio-immunoblastic T cell lymphoma (AITL). A clone specific
population of B lymphocytes may be demonstrated in an estimated 41% instances
with concomitant angio-immunoblastic T cell lymphoma. Competent molecular
investigation of the lymphoma may discern genetic manifestations of AITL and
demarcates it from categories of peripheral T cell lymphoma (PTCL) [8,9]. The
molecular fabrication of AITL comprises of follicular dendritic cells (FDCs), B
lymphocytes and an interwoven stroma. Tumor specific microenvironment defines
the prognostic outcomes of the lymphoma (AITL).
Gene expression profiling (GEP) may appropriately delineate
multitudinous genetic aberrations such as TET2 (47%-73%), DN MT 3A (33%) and
IDH2-R172 (20-40%). The anomalies may distinguish AITL from certain B cell
lymphomas with the recapitulation of specific myeloid malignancies [2,3].
However, these mutations may be inadequate to initiate the specific lymphoma.
Functional mutations with chromosomal gains within the T cell receptors of AITL
may be exemplified. RHOA, a specific GTPase, incriminated in the rearrangement
of cellular cytoskeleton may be mutated (G17v) in an estimated 60% instances of
AITL. RHOA and TET2 mutation may coexist thereby inciting multitudinous genetic
aberrations within AITL, which may be enunciated in various stages of T cell
development [2,3] (Figures 1-13).
INVESTIGATIVE ASSAY
Diagnostic manifestations may include pancytopenia, circulating immune
complexes, anti-smooth muscle antibodies, autoimmune hemodialysis, the presence
of cold agglutinin, para-protein and emerging anti-cardiolipin antibodies. The
appearance of rheumatoid factor and cryo-globulins may be exceptional. Majority
of instances display an elevated erythrocytes sedimentation rate (ESR) with
elevated serum lactate dehydrogenase (LDH). Polyclonal gammo-globulins may
concur with a reactive direct coombs/anti-globulin test (DAT) [8,9]. Attributes
favoring a diagnosis of AITL may incorporate
itching, rashes, fever, weight loss, cervical lymph node enlargement,
pancytopenia, autoimmune hemolysis, a positive direct coombs test (DCT+),
elevated erythrocyte sedimentation rate (ESR), serum lactate dehydrogenase
(LDH) and total serum protein, a decline
in serum albumin, a positive C-reactive protein (CRP) and reactive anti-nuclear
antibodies (ANA) [2,3]. Radiographic elucidation of the lymphoma may discern a
bilateral mediastinal and hilar lymph node enlargement, pleural effusion,
interstitial and alveolar opacities with atelectasis. A plain X-ray chest may
demonstrate bilateral reticulo-nodular opacities. Computerized tomography (CT)
scan of the thorax may exhibit bilateral nodular opacities with patchy
consolidation of the lung parenchyma. Mediastinal lymph node enlargement may
coexist [9,10]. Computerized tomography (CT) scan of the abdomen may depict a
lymph node enlargement with a concomitant histology of cervical lymph nodes
[10,11].
PROGNOSTIC OUTCOMES
Angio-immunoblastic T cell (AITL) may be considered as a diverse
peripheral T cell lymphoma (PTCL). Median 5 year survival of the lymphoma
(AITL) appears at an estimated (32%). The international prognostic index (IPI),
as applicable for aggressive B lymphocyte Non-Hodgkin’s lymphoma, may exhibit a
5 year overall survival (OS) of 56% for individuals with an IPI score of 0/1 and
a 5 year overall survival (OS) of 25% for an IPI score of 4/5. The prognosis in
AITL (PIA) score may incorporate distinct parameters such as age above 60
years, Eastern Cooperative Oncology Group (ECOG) performance status greater
than two, site of extra-nodal disease greater than one, occurrence of B
symptoms and a platelet count below 150 × 10ᶺ9/L. A “low risk group” may be
defined with manifested 0-1 probable factors and a 5 year overall survival (OS)
of 44%. A concomitant “high risk group” may be distinguished with the emergence
of 2-5 probable factors and a concordant overall survival (OS) of 24%. The
applicability of a prognostic index may elucidate appropriate adaptations of
risk specific therapeutic options [2,3].
THERAPEUTIC APPROACH
Angio-immunoblastic T cell lymphoma (AITL) may respond to suitable
induction therapy. Therapeutic options may include single agent oral therapy or
a combination of intensive chemotherapeutic agents. The treatment protocols may
induce primary progression of disease or brief periods of remission. Recent
diagnosed lymphoma (AITL) may lack the application of specific chemotherapeutic
agents. Prognosis in AITL (PIA) may be benefitted by risk adapted therapeutic
strategies. Clinical trials may be appropriately employed. A first line
treatment with an anthracycline based regimen may delineate a complete
remission (CR) of 61% and 5 year survival of 32% with a recurrence free
survival of 18% [11,12]. The classic combination of cyclophosphamide,
doxorubicin, vincristine and prednisone (CHOP) may singularly appear as a gold
standard of therapy with AITL, though specific subclasses of lymphoma may
elucidate an inferior prognosis. The chemotherapeutic regimen of CHOP may be
considered suitable for the first line management of AITL, particularly when
subsequent to ineffective anthracycline based therapies. The regimen of CHOP
may induce a complete remission (CR) of 53% with AITL (39% with PTCL) [3]. A
competent induction therapy for PTCL with an objective response rate (ORR) of
82% and complete remission (CR) of 51% may be constituted by concomitant
employment of cyclophosphamide, doxorubicin, vincristine, etoposide and
prednisone (CHOEP). However, the remission and response rates of AITL subjected
to a CHOEP therapy may not be currently available. Therapeutic CHOEP may
enhance the remission for subsequent application of an elevated
chemotherapeutic dosage and autologous stem cell rescue (HDT-ASCR) [3].
Solitary agents may be employed in combination with CHOP regimen such as romidepsin
(romidepsin CHOP or Ro CHOP). A complete remission (CR) of 51% and a median
progression free survival (PFS) of 21 months may be achieved in PTCL.
Belinostat may be employed as a singular drug along with CHOP. The complete
remission (CR) induced by the combination may extend up to 67% with PTCL
[12,13]. Pralatrexate may be an alternative sole agent adjunctive to CHOP and
employed in clinical trials. The concurrence of doxorubicin, cyclophosphamide,
vindesine, bleomycin and prednisone (ACVBP) may prove to be superior to
chemotherapy with CHOP. Bortezomib (proteasome inhibitor) as a singular therapy
may be employed concomitantly with CHOP and ACVBP regimens. An objective
response rate (ORR) of 76% and a complete remission (CR) of 65% may be elucidated
with PTCL. An estimated 17% incidence of AITL may depict an augmented 3 year
overall survival (OS). The regimen of dose adjusted etoposide, prednisone,
vincristine, cyclophosphamide and doxorubicin (DA-EPOCH) may be recommended by
the National Comprehensive Cancer Network (NCCN) guidelines [11,13]. It may be
surmised that a non anthracycline regimen may prove to be superior for managing
PTCL. The regimen of cisplatin, etoposide, gemcitabine and methyprednisolone
(PEGS) may delineate an inadequate objective response rate (ORR) of 39% with
AITL. A median progression free survival (PFS) may be exhibited at 7 months. A
regimen of alternating cyclophosphamide, etoposide, vincristine and prednisone
(CEOP) with pralatrexate may depict a 2 year progression free survival (PFS) of
39% and a complete remission (CR) of 25% with AITL [3]. Avastin as an
antagonist of the vascular endothelial growth factor (VEGF) may be combined
with the CHOP regimen (Av-CHOP). The combination therapy may depict a complete
response (CR) of 49% and a progression free survival (PFS) of 44% at 1 year.
However, the particular regimen may be significantly cardio-toxic. An anti CD20
monoclonal antibody termed as rituximab may be utilized with the regimen of
CHOP (R-CHOP). The combined therapy may display an objective response rate
(ORR) of 80%, a complete remission (CR) of 44% or the CR remains unconfirmed.
Overall survival (OS) at 2 years may be observed at 62% [10,12]. An anti CD52
monoclonal antibody Alemtuzumab may be employed with the therapeutic regimen of
(CHOP). The monoclonal antibody may adhere to the T and B lymphocytes which
enunciate the CD52 molecule. A complete response (CR) of 66% may be achieved.
Lymphomas engendered by the opportunistic viruses’ cytomegalovirus (CMV) or
Epstein Barr virus (EBV) may concomitantly be elucidated. Superimposed
infections and non-hematological complications may additionally ensue following
immune suppression with chemotherapy. An immunomodulatory agent such as
lenalidomide may be beneficial when employed singularly. It may be successfully
combined with the CHOEP regimen. Lenalidomide may be used singularly as
maintenance therapy. Currently diagnosed AITL may be managed with concurrent
lenalidomide and CHOP [12,13]. AITL may be chemo-sensitive to the employment of
high dose chemotherapy with autologous stem cell rescue (HDT-ASCR) as discerned
by computerized tomography (CT) or a positron emission tomography (PET-CT). The
chemo-sensitive instances of AITL may exhibit a definite survival advantage. An
induction regimen employing CHOEP along with HDT-ASCR may be applicable for
individuals of AITL with intent to treat or transplant. The subjects may
comprehensively delineate a 5 year progression free survival (PFS) of 49% and
an overall survival (OS) of 52%. Such individuals may be described as having a
“maximal chemotherapeutic exposure” [3].
RELAPSED AND REFRACTORY
ANGIOIMMUNOBLASTIC T CELL LYMPHOMA
A challenging disease to treat, refractory or relapsed AITL may
enunciate a median overall survival (OS) of 5.5 months, particularly in
subjects lacking HDT-ASCR following acceptable induction therapy. Regimens such
ifosphamide, carboplatin, etoposide (ICE) dexamethasone, cytarabin, cisplatin
(DHAP) or etoposide, methyl-prednisone, cisplatin, cytarabine (ESHAP) may be
employed for managing the refractory/relapsed instances [3]. Regimens
applicable to out-patients may incorporate gemcitabine, cisplatin, methylprednisolone
(Gem-P) and gemcitabine, cisplatin dexamethasone (GDP). Singular agent
bendamustine may also be advantageous. The aforementioned efficacious regimens
may mandate additional evaluation in patients of AITL [11,13]. Concurrent
chemotherapies may depict an augmented objective response rate (ORR), such as
that of 70% with the administration of ICE. Emerging hematological toxicities
may restrict the combined chemotherapies to 3-4 cycles with a diminished
progression free survival (PFS). Patients who are “transplant eligible” may
benefit from the combined therapeutic option which permits an appropriately
timed HDT-ASCR in chemo-sensitive subjects. Continuous therapy applicable until
progression of disease or therapeutic intolerance may be opted for treating
AITL. The technique may be applicable to singular agents with an objective of
maintenance of quality of life [10,12]. Drug conjugate pralatrexate may depict
an objective response rate (ORR) of 8% in AITL, thus may be acceptable for a
combination therapy or a clinical trial. Romidepsin as a solitary agent may
demonstrate an objective response rate (ORR) of 30% in AITL. A median duration
of response (DOR) of 17 months may be achieved with romidepsin. Belinostat as a
second histone deacetylase (HDAC) inhibitor may be administered in AITL. An
objective response rate (ORR) of 45% may be elucidated as AITL delineates a
minimally intense CD30+ phenotype, in contrast to a greater CD30+ enunciation
with anaplastic large cell lymphoma (ALCL). Drug conjugate brentuximab vedotin
may depict an objective response rate (ORR) of 54% with AITL [3]. Cyclosporine
as an immune suppressive agent may be utilized in AITL with an objective
response rate (ORR) of 75%. Immune-modulatory agent lenalidomide may be
appropriate for managing refractory or relapsed AITL. The achieved objective
response rate (ORR) may be at 29% with the emergence of partial remission.
Romidepsin and Belinostat may be employed as FDA approved singular therapies
for treating refractory or relapsed instances of AITL. However, the agents may
not be efficacious as front line therapy for treating refractory AITL in
combination with CHOP. Novel therapies such as Janus Kinase (JAK 2) inhibitors,
hypo-methylating agents and isocitrate dehyrogenase 2 (IDH2) inhibitors may
prove to be efficacious in clinical trials [3] (Table 1).
1.
Swerdlow SH, Campo E,
Pileri SA, Harris NL, Stein H, et al. (2016) The 2016 revision of world health
organization classification of lymphoid neoplasm. Blood 127: 2375-2390.
2.
Mohanty A, Majhi M,
Sahu PK, Panchari PK, Dinakar Y, et al. (2018). Angio-immunoblastic T cell
lymphoma: Typical presentation of an atypical disease. J Immunol Forecast 1:
1004.
3.
Lunning MA, Vose MJ
(2017) Angio-immunoblastic T cell lymphoma: The many faced lymphoma. Blood.
4.
Rosai, Ackerman (2016)
Surgical Pathology. Tenth Pathology, p: 1798.
5.
Frederico M, Rudioger
T, Bellei M, Bharat N, Luminari S, et al. (2013) Clinicopathologic
characteristics of angio-immunoblastic T cell lymphoma: analysis of the
international peripheral T cell lymphoma project. J Clin Oncol 10:
240-246.
6.
Huppmann AR, Roullet
MR, Raffeld M, Jaffe ES (2013) Angio-immunoblastic T cell lymphoma partially
obscured by an Epstein Barr virus negative clonal plasma cell proliferation. J
Clin Oncology 10: e28-30.
7.
Loghavi S, Wang SA,
Medeiros LJ, Jorgensen JL, Li X, et al. (2016) Immunophenotypic and diagnostic
characterization of angio-immunoblastic T cell lymphoma by advanced flow
cytometric technology. Leukemia and Lymphoma 57: 2804-2812.
8.
Vallois D, Dobay MP, Morin
RD, Lemonnier F, Missiaglia E, et al. (2016) Activating mutations in genes
related to TCR signalling in angio-immunoblastic and other follicular helper T
cell derived lymphomas. Blood 128: 1490-502.
9.
Horwitz SM, Zelenetz AD
Gordon LI, Wierda WG, Abramson JS, et al. (2016) NCCN guidelines insight:
Non-Hodgkin’s lymphoma version 3-2016. J Natl Compr Canc Netw 14:
1067-1079.
10.
Feeney J, Horwitz S
Gönen M, Schöder H (2010) Characterization of T cell lymphoma by FDG PET/CT.
AJR Am J Roentgenol 195: 333-340.
11.
11. Casulo C, Schoder
H, Feeney J, Lim R, Maragulia J, et al (2013) 18 F-flouorodeoxy glucose
positron emission tomography in the staging and prognosis of lymphoma. Leukemia
and Lymphoma 54: 2163-2167.
12.
de Leval L,
Gisselbrecht C, Gaulard P (2010) Advances in the understanding and management
of angio-immunoblastic T cell lymphoma. Br J Hematol 148: 673-689.
13.
Advani RH, Ansell SM,
Lechowicz MJ, Beaven AW, Loberiza F, et al (2016) A phase II study of
Cyclophosphamide, Etoposide, Vincristine and Prednisone (CEOP) alternating with
Pralatrexate (P) as front line therapy for patients with peripheral T-cell
lymphoma (PTCL): Final results from the T-cell consortium trial. Br J Hematol
172: 535-544.
QUICK LINKS
- SUBMIT MANUSCRIPT
- RECOMMEND THE JOURNAL
-
SUBSCRIBE FOR ALERTS
RELATED JOURNALS
- Journal of Carcinogenesis and Mutagenesis Research (ISSN: 2643-0541)
- International Journal of Medical and Clinical Imaging (ISSN:2573-1084)
- Journal of Ageing and Restorative Medicine (ISSN:2637-7403)
- Chemotherapy Research Journal (ISSN:2642-0236)
- Journal of Otolaryngology and Neurotology Research(ISSN:2641-6956)
- International Journal of Diabetes (ISSN: 2644-3031)
- Journal of Cancer Science and Treatment (ISSN:2641-7472)